This study is being conducted to evaluate the safety and efficacy of JZP926 capsule in participants with Juvenile Myoclonic Epilepsy (JME).
Is ≥ 10 years of age at the time of screening.
Has a diagnosis of JME per ILAE criteria as specified in the protocol.
Has at least 4 myoclonic seizure days per 28 days historical seizure frequency.
Presence of seizure types other than GTC, myoclonic, and absence seizures.
If historical MRI has been performed, participant's MRI reveals a cause of epilepsy other than JME.
Has a concurrent, confirmed diagnosis of non-epileptic seizures or events that can confound the assessment of the efficacy measures, in the opinion of the investigator.
The etiology of the participant's seizures is a progressive neurologic disease.